IVA Stock Price and Chart — NASDAQ:IVA — TradingView

Compare with Inventiva S.A. - American Depository Shares

Key stats

Upcoming earnings

Company info

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

Inventiva continues its upward trajectory :) :)The psychological level of €5 is now acting as support. The fundamentals for the MASH treatment are very strong. Phase 3 is progressing as planned. Next target: €7.50. Although €10 doesn't seem unreasonable for the end of the year. Now's the time to buy, guys, before the final surge.

Inventiva (IVA): The MASH Turnaround Play – 200% potential.Summary: Inventiva SA is showing a compelling turnaround setup on the daily timeframe. After a prolonged accumulation period in the $3.50–$4.50 range, the price has successfully reclaimed key moving averages and broken out of a massive volume shelf. Backed by strong analyst upgrades (UBS, Leerink) a

Inventiva faces resistance but has solid fundamentals On an uptrend near the 210-day MA (30 weeks) (Wall around €5) . Key takeaways: - Clinical advances on lanifibranor - Financing and partnerships (including rumors from US pharmaceutical giants) - Cash flow increasing until mid-2026. Analysts' speculative price target around €8. Everything will depe

IVA We are retracing to the 200 Ma which also happens to be the 1.272 fib. this offers a short opportunity of 8.57%. Nothing I say is financial advice.

Ichimoku entry IVA One of the less common entries where the cloud twist is the trigger

Possibility of strong rise, but beware of speculators This increase of more than 30% of November 1 is not obtained as a result of news concerning Inventiva, caution, therefore, following the speculators who can in the short term vary the action. In the long run, I think it's a big possibility if the products work and the tests succeed one after the ot

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

Neutral

Neutral

An aggregate view of professional's ratings.

Neutral

Neutral

Neutral

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock

Weight1.34%

Market value‪1.06 M‬

Weight0.27%

Market value‪114.57 K‬

Weight0.00%

Market value‪46.63 K‬

Weight0.27%

Market value‪42.77 K‬

Explore more ETFs